Litcius/Paper detail

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui, Alessandro M. Vannucchi, Alberto Álvarez‐Larrán, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Alberto Ferrari, Giuseppe Rossi, Elena Maria Elli, Marcio Andrade‐Campos, Mercedes Gasior Kabat, Jean-Jaques Kiladjian, Francesca Palandri, Giulia Benevolo, Valentín García‐Gutiérrez, María Laura Fox, María Ángeles Foncillas, Carmen Morcillo, Elisa Rumi, Santiago Osorio, Petros Papadopoulos, Massimiliano Bonifacio, Keina Quiroz Cervantes, Miguel Sagüés Serrano, Gonzalo Carreño‐Tarragona, Marta Sobas, Francesca Lunghi, Andrea Patriarca, Begoña Navas Elorza, Anna Angona, Elena Magro Mazo, Steffen Koschmieder, Marco Ruggeri, Beatriz Cuevas, Juan Carlos Hernández‐Boluda, Emma Lopez Abadia, Blanca Xicoy Cirici, Paola Guglielmelli, Marta Garrote, Daniele Cattaneo, Rosa Daffini, Fabrizio Cavalca, Beatríz Bellosillo, Lina Benajiba, Natalia Curto‐García, Marta Bellini, Silvia Betti, Valerio De Stefano, Claire Harrison, Alessandro Rambaldi

2021Leukemia82 citationsDOIOpen Access PDF

Topics & Concepts

MedicineRuxolitinibMyelofibrosisEssential thrombocythemiaInternal medicinePolycythemia veraUnivariate analysisMortality ratePopulationCoronavirus disease 2019 (COVID-19)Survival analysisMultivariate analysisDiseaseBone marrowInfectious disease (medical specialty)Environmental healthMyeloproliferative Neoplasms: Diagnosis and TreatmentHemoglobinopathies and Related DisordersChronic Myeloid Leukemia Treatments
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib | Litcius